Last $9.46 USD
Change Today -0.368 / -3.74%
Volume 105.9K
LMNS On Other Exchanges
As of 4:30 PM 04/24/14 All times are local (Market data is delayed by at least 15 minutes).

lumenis ltd - b (LMNS) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/27/14 - $13.38
52 Week Low
04/15/14 - $8.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for LUMENIS LTD - B (LMNS)

Related News

No related news articles were found.

lumenis ltd - b (LMNS) Related Businessweek News

No Related Businessweek News Found

lumenis ltd - b (LMNS) Details

Lumenis Ltd, together with its subsidiaries, develops and commercializes energy-based medical systems. The company operates in three segments: Surgical, Ophthalmic, and Aesthetic. The Surgical segment offers various surgical laser systems and accessories used for urology/genitourinary and ENT to hospitals, outpatient clinics, ambulatory surgery centers, and medical practices. The Ophthalmic segment sells ophthalmology laser systems and accessories, such as laser links, slit lamp microscopes, laser indirect ophthalmoscopes, physician eye safety filters, surgical laser probes, and others to ophthalmic practices, outpatient clinics, and ophthalmology departments of hospitals, primarily for use in retinal treatment and glaucoma/secondary cataract applications, as well as for refractive applications. The Aesthetic segment offers aesthetic laser energy-based systems to physicians, primarily for skin treatment and hair removal applications. The company also provides technical training and certification of field service engineers and distributor service personnel; operates communications centers that perform installation, maintenance, and periodic and preventive servicing activities; publishes and controls the technical documentation, including service manuals and technical bulletins; and provides spare parts and logistics channels. It markets its products through a network of third-party distributors, direct sales force, and independent distributors in the Americas, Japan, the Asia pacific, Europe, the Middle East, and Africa. The company was formerly known as ESC Medical Systems Ltd. and changed its name to Lumenis Ltd. in September 2001. Lumenis Ltd. was founded in 1991 and is headquartered in Yokneam, Israel.

1,061 Employees
Last Reported Date: 02/28/14
Founded in 1991

lumenis ltd - b (LMNS) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

lumenis ltd - b (LMNS) Key Developments

Lumenis Ltd. Introduces the Lumenis Pulse(TM) 120H Holmium Laser Platform

Lumenis Ltd. announced the introduction of the Lumenis Pulse(TM) 120H Holmium laser platform. With unrivaled power, speed, safety and versatility, the Lumenis Pulse(TM) 120H (120 W, 80 Hz and 6J) provides physicians performing urological procedures with a superior product enabling excellent clinical results and greater return on investment. The new platform debuts at the 29th Annual European Association of Urology (EAU) Congress. The Lumenis Pulse(TM) 120H is the optimal platform for preforming enhanced Vaporization, Enucleation, Flexible Ureteroscopy and Percutaneous Nephrolithotomy (PCNL) procedures. The Lumenis Pulse(TM) 120H will make HoLEP procedures more precise, faster and efficient. The Lumenis Pulse(TM) 120H Platform is accompanied by a range of new fibers and accessories, enabling improved clinical outcomes, reduced treatment time and increased patient satisfaction. They include: The Xpeeda(TM) fiber - improves energy utilization and accelerates vaporization rate. The SlimLine(TM) 200 fiber - sets new standards for flexibility, efficiency and durability, thus improving Stone-Dusting(TM) capabilities. The VersaCut+(TM) Tissue Morcellator, which is safer, faster, more intuitive and cost-effective. A new simulator designed to train Urologists on the HoLEP procedure. The HoLEP Disposables Kit - contains all needed HoLEP instruments in one compact package. The Lumenis Pulse(TM) 120H is the new addition to Lumenis comprehensive portfolio for BPH and stones laser-based solutions. Lumenis continues to offer the entire portfolio which includes, among others, the following platforms, to address various market needs:The VersaPulse(R) P20 (20W), which is a cost effective solution mainly for Stones; The VersaPulse(R) PowerSuite(TM) (100W), which is mainly used for Flexible Ureteroscopy, including stone dusting capabilities, and BPH Enucleation; The Lumenis Pulse(TM) 120H platform (120 W, 80 Hz and 6J), a comprehensive solution designated to be used for BPH Enucleation, Vaporization of the prostate, Stone Flexible Ureteroscopy, including stone dusting capabilities and PCNL.

Lumenis Introduces LightSheer(R) INFINITY(TM) and LightSheer(R) DESIRE(TM) Laser Hair Reduction Products to the European Market at the Anti-Aging Medicine World Congress

Lumenis Ltd. announced that the new LightSheer(R) INFINITY(TM) and LightSheer(R) DESIRE(TM) laser hair reduction products will be introduced in Europe at the 12th Anti-Aging Medicine World Congress (AMWC), taking place in Monte-Carlo on April 3-5, 2014. The new products will also be featured at the American Society for Laser Medicine and Surgery (ASLMS) Annual Conference, taking place in Phoenix, Arizona on April 2-6, 2014. Attendees at the meetings can visit the Lumenis booth, # B4 at AMWC and # 509 at ASLMS, for demonstrations of the new products. Both LightSheer(R) INFINITY(TM) and LightSheer(R) DESIRE(TM) are up to 75% faster than other available devices and use Lumenis' proprietary HIT(TM) (High-Speed Integrated Technology) and ChillTip(TM) technologies for enhanced efficacy and patient comfort. LightSheer(R) INFINITY(TM) is Lumenis' most advanced laser hair removal workstation. It features two gold-standard wavelengths, 805nm for all skin types, and 1060nm, the optimal solution for tanned and dark skin types. LightSheer(R) DESIRE(TM) is both portable and upgradable, enabling users to add new capabilities as their practice grows. The advanced user interface allows easy treatment delegation and a quick learning curve. Lumenis' existing laser hair reduction solutions, the LightSheer(R) DUET(TM) and LightSheer(R) ET, are recognized as industry gold standards. More than 50 peer reviewed articles confirm the superior efficacy, safety, comfort and high patient satisfaction achieved with LightSheer products. In addition to the expansion of the LightSheer(R) franchise, Lumenis will also be featuring a new addition to the M22(TM) multi-application platform, the Q- Switched Nd:YAG module, at the Anti-Aging Medicine World Congress. The Q-Switched Nd:YAG module is designed for skin toning (by treatment of pigmented lesions), dark tattoo removal and can also be used for advanced combination treatments with other M22(TM) modalities. This cost-effective upgrade to the M22(TM) platform features five spot sizes for versatility in applications and a top-hat, homogenous beam profile for optimal patient safety.

Lumenis Introduces Expanded Versatility in Skin Treatments with the New Q-Switched Nd:YAG Module for the M22(TM) Multi-Application Platform

Lumenis Ltd. announced the introduction of a new Q-Switched Nd:YAG module for the M22(TM) platform. M22(TM) is the modular multi-application platform for the treatment of over 30 skin conditions and hair removal. The Q-Switched Nd:YAG module is designed for skin toning (by treatment of pigmented lesions), dark tattoo removal and can also be used for advanced combination treatments with the other M22(TM) modalities. This cost-effective upgrade to the M22(TM) platform features five spot sizes for use across a wide variety of applications and a top-hat, homogenous beam profile for optimal patient safety. The M22(TM)'s enhanced capabilities address the need for new aesthetic skin procedures, which was highlighted in a recent consumer survey conducted by the American Society for Dermatologic Surgery. The survey found that 62% of respondents are bothered by skin texture/color, of which 19% are extremely bothered. The survey also revealed that 74% are considering a laser/light procedure to reduce facial redness, improve skin tone or improve scars from acne/injury. The Q-Switched Nd:YAG is the second new module introduced for the M22(TM) platform over the last year. The ResurFX(TM) module, which received FDA clearance in September 2013, allows the M22(TM) to perform true fractional non-ablative skin resurfacing. ResurFX(TM) uses a 1565 nm fiber laser and a unique CoolScan(TM) scanner, which, unlike other non-ablative fractional technologies, enables a homogeneous and uniform pattern of coagulation columns, and requires only one pass. This feature saves practitioners' time and helps protect the patient's skin.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LMNS:US $9.46 USD -0.368

LMNS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LMNS.
View Industry Companies

Industry Analysis


Industry Average

Valuation LMNS Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LUMENIS LTD - B, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at